Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Payables (2016 - 2025)

Jaguar Health (JAGX) has disclosed Payables for 11 consecutive years, with $36.1 million as the latest value for Q4 2025.

  • Quarterly Payables rose 108.53% to $36.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.1 million through Dec 2025, up 108.53% year-over-year, with the annual reading at $36.1 million for FY2025, 108.53% up from the prior year.
  • Payables for Q4 2025 was $36.1 million at Jaguar Health, up from $31.6 million in the prior quarter.
  • The five-year high for Payables was $36.1 million in Q4 2025, with the low at $5.6 million in Q3 2021.
  • Average Payables over 5 years is $16.4 million, with a median of $15.6 million recorded in 2024.
  • The sharpest move saw Payables plummeted 57.3% in 2021, then skyrocketed 223.73% in 2022.
  • Over 5 years, Payables stood at $8.1 million in 2021, then surged by 167.36% to $21.7 million in 2022, then tumbled by 54.63% to $9.8 million in 2023, then soared by 76.04% to $17.3 million in 2024, then soared by 108.53% to $36.1 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $36.1 million, $31.6 million, and $25.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.